Sun Pharma Q2 results: net profit falls 36% to Rs 1,988.5 crore, sales up 11.8%
Sun Pharma's consolidated profit after tax fell 36.2% to Rs 1,988.5 crore in the September 2026 quarter, its NSE filing shows, while sales rose 11.8% to Rs 16,100 crore.
Key points
- Sun Pharmaceutical Industries filed its results for the quarter ended 30 September 2026 with the National Stock Exchange on 30 October 2026.
- Reported profit after tax fell 36.2% to Rs 1,988.5 crore, while adjusted profit after tax rose 1.4% to Rs 3,162 crore, per the filing.
- Sales rose 11.8% to Rs 16,100 crore; the company said its proposed Organon acquisition is indicated to close by the fourth quarter of 2026-27.
Photo: BuhaM / Wikimedia Commons, CC BY-SA 4.0 (cropped). Representational image.
Sun Pharmaceutical Industries reported a consolidated profit after tax of Rs 1,988.5 crore for the quarter ended 30 September 2026, 36.2% lower than the Rs 3,118 crore it reported a year earlier, according to the results and earnings presentation it filed with the National Stock Exchange on 30 October 2026. Sales rose 11.8% to Rs 16,100 crore from Rs 14,405.2 crore. The company also reported an adjusted profit after tax of Rs 3,162 crore, up 1.4%.
What Happened
Sun Pharma's board approved the unaudited standalone and consolidated results for the second quarter of 2026-27 (Q2 FY27) at its meeting on 30 October 2026. Per the earnings presentation, EBITDA (earnings before interest, tax, depreciation and amortisation, a measure of operating profit) rose 4.8% to Rs 4,743.9 crore from Rs 4,527.1 crore, while the EBITDA margin fell to 29.3% from 31.3%. Earnings per share were Rs 8.3, against Rs 13.0 a year earlier.
For the half year ended 30 September 2026, sales rose 11.0% to Rs 31,283.6 crore, and reported profit after tax fell 9.5% to Rs 4,883.3 crore from Rs 5,396.6 crore.
By market, the company said India formulations grew 17% in the quarter and made up 34.5% of consolidated sales, with 14 new products launched in India. US formulations declined 8.2% to US$ 455 million, which the presentation linked to erosion in sales of lenalidomide. Emerging-markets revenue rose 7.6% to US$ 350 million, and the global innovative medicines business grew 6.9%.
What It Means
Shareholders see two profit figures this quarter: on the company's adjusted measure, profit was broadly unchanged from a year earlier, while reported profit fell by more than a third. The company said it had a net cash position of US$ 3.3 billion and had allotted its first non-convertible debentures (bonds that cannot be converted into shares), worth Rs 7,816 crore.
On its proposed acquisition of Organon, signed on 27 April 2026, the company said approvals had been received for most filings, a few were still pending, and it indicated closure by the fourth quarter of 2026-27. Until then, the two will work as independent entities. The results are unaudited and were reviewed by the statutory auditors, as the filing shows.
Sources & Citations
- NSE filing: Q2 FY27 financial results — National Stock Exchange of India